UR President Joel Seligman sent a message to the University community last Wednesday, Jan. 16, announcing that he had completed radiation treatments for a curable form of B Cell Non-Hodgkins Lymphoma.

According to his doctor, Director of the James P. Wilmot Cancer Center Richard Fisher, Seligman is in complete remission with no evidence of cancer at this time.

“While there are no absolute guarantees in life,” Seligman said in the message, “the recurrence rate for the type of Non-Hodgkins Lymphoma that I have is quite low.”

Seligman was diagnosed last summer and publicly announced his illness on Aug. 21, 2007. The cancer was detected in stage 1A, an early stage of the disease, and the initial prognosis was optimistic.

On Dec. 21, Seligman completed his 28th and final radiation session, and he has since begun follow-up and monitoring.

He thanked the many medical workers who helped in his treatment.

“Let me express my gratitude to Drs. Fisher, Louis (Sandy) Constine, my radiation oncologist and Ray Mayewski, my personal physician, and the great nurses, technicians and staff at the Wilmot Cancer Center and Strong Memorial Hospital for the wonderful care and treatment that they provided,” Seligman said. “I am truly fortunate to be associated with a University that has such an outstanding hospital.”

He also recognized the University community that stood behind him during this time.

“Let me also express my deep appreciation for the support that the University community has given me over the past few months,” he said. “I look forward to working long into the future with you to continue to strengthen the University of Rochester.”

Wrobel is a member of the class of 2010.



UR Pet Rock is growing

Pet Rock is young, scrappy, and hungry. As the club is entering its fourth semester since its launch, they’re looking for new members.

The steep price of health and wellness

Instead of shaming others for not epitomizing stereotypical health and wellness, we must meet every individual where they are at.

Congestion Pricing: Not as good as it seems

Congestion pricing is a promising idea, and I have no problems with it in and of itself, but the MTA should  have expanded its service and responded to its underlying safety issues before pushing people into its system.